Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Department of Gastrointestinal Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Med. 2021 Jun;10(11):3741-3755. doi: 10.1002/cam4.3901. Epub 2021 May 2.
This case-control study was aimed to investigate associations between HBV infection and extrahepatic digestive system cancers.
The patients of gastric, small intestinal, colonic, rectal, anal, biliary tract, and pancreatic cancers were retrospectively collected between 2016.5 and 2017.12. Simultaneously, the healthy controls were collected from the health check-up registry, and cancer-free status was confirmed based on medical records. Propensity score matching was performed to reduce bias. Multinomial logit model and conditional logistic regression model were used to assess the risk of individual cancer according to HBV serological markers and classifications.
Totally, 4748 patients involving seven cancers, and 57,499 controls were included. After matching, HBsAg was associated with increased risk of gastric cancer (aOR = 1.39, 95% CI: 1.05-1.85), and anti-HBs served as a protective factor for gastric (aOR = 0.72, 95% CI: 0.61-0.85), colonic (aOR = 0.73, 95% CI: 0.60-0.89), rectal (aOR = 0.73, 95% CI: 0.63-0.85), and pancreatic (aOR = 0.58, 95% CI: 0.42-0.82) cancers. Compared to subgroups with non-infection and vaccination status, inactive HBsAg carriers and active HBV infection subgroup were correlated with gastric carcinogenesis (aOR = 1.41, 95% CI: 1.03-1.93). However, no clear association was found between HBV infection and other cancers.
HBV infection was potentially associated with an increased risk of gastric cancer. The development mechanism of HBV-associated gastric cancer needs to investigate further.
本病例对照研究旨在探讨乙型肝炎病毒(HBV)感染与肝外消化系统癌症之间的关系。
本研究回顾性收集了 2016 年 5 月至 2017 年 12 月期间胃、小肠、结肠、直肠、肛门、胆道和胰腺癌症患者,并同时从健康检查登记处收集了健康对照者,且基于病历确认其无癌症病史。采用倾向评分匹配法以减少偏倚。采用多项逻辑回归模型和条件逻辑回归模型根据 HBV 血清标志物和分类评估个体癌症的发病风险。
本研究共纳入了 4748 例 7 种癌症患者和 57499 例对照者。匹配后,HBsAg 与胃癌风险增加相关(调整比值比[aOR] = 1.39,95%可信区间[CI]:1.05-1.85),而抗-HBs 则是胃癌(aOR = 0.72,95%CI:0.61-0.85)、结肠癌(aOR = 0.73,95%CI:0.60-0.89)、直肠癌(aOR = 0.73,95%CI:0.63-0.85)和胰腺癌(aOR = 0.58,95%CI:0.42-0.82)的保护因素。与非感染和未接种疫苗亚组相比,HBsAg 非活动携带者和 HBV 活跃感染者亚组与胃癌的发生相关(aOR = 1.41,95%CI:1.03-1.93)。然而,HBV 感染与其他癌症之间无明显关联。
HBV 感染可能与胃癌风险增加相关。HBV 相关胃癌的发病机制需要进一步研究。